Oncorus — Investor Presentation (January 2022)
24 slides from Oncorus's investor presentation, Jan 10, 2022
Slide 1: Viral Immunotherapies for Cancer
Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the current beliefs, expectations and assumptions of Oncorus, Inc. (the “Company”) regarding the future of its business, its future plans and str
Slide 3: Heating Up Tumors via Therapeutic Infections
Heating Up Tumors via Therapeutic Infections Innovative Herpes Simplex Viruses Uniquely engineered to safely retain replication and express 5 immunomodulatory payloads Rapid clinical benefit demonstrated in 3/8 patients thus far with ONCR-177 monotherapy Intratumoral Synthetic RNA Viruses Selectivel
Slide 4: Dual-Platform Informs Robust Pipeline
Dual-Platform Informs Robust Pipeline Candidate Platform RoA Indications Discovery IND-Enabling Phase 1 Phase 2 Phase 3 ONCR-177 IL-12, FLT3L, CCL4, aPD-1 & aCTLA-4 HSV iTu Head & Neck Melanoma Triple Neg. Breast ONCR-021 Synthetic CVA21 vRNA IV Non-small cell lung Renal cell Melanoma Hepatocellular
Slide 5: ONCR-177 Clinical Development Plan
Part A: Monotherapy Part B: Combination with ONCR-177 Phase 1 (KEYNOTE-B73) Clinical Development Plan Randomized Trial(s) 3L TNBC 2L Melanoma 2L Head & Neck ONCR-177 is dosed iTu every 2 weeks for up to 26 doses (NCT04348916); RP2D=Recommended Phase 2 Dose=4E8 for surface lesions; TNBC=triple negati
Slide 6: ONCR-177 Phase 1 Monotherapy Provide Early Signs of Clinical Benefit
ONCR-177 Phase 1 Monotherapy Provide Early Signs of Clinical Benefit Cut off date: 01Nov2021 Duration of Treatment (Months) CR PR SD PD Death Ongoing Not Evaluable Dose Escalation Cohort 4 (4x108 PFU in 4mL) RP2D Dose Expansion Cohorts (4x108 PFU in 4mL) RP2D
Slide 7: ONCR-177 Phase 1 Monotherapy Results Provide Early Signs of Clinical Benefit
Patient 2L Melanoma (4-8) 3L HPV+ SCCHN (4-7) 2L Melanoma (4-6) Prior therapy Relapse after adjuvant nivolumab 2 prior lines including pembrolizumab + platinum ipilimumab + nivolumab, nivolumab Week 4 classification Tumor regression in both lesions, partial response in larger lesion (measurable per
Slide 8: ONCR-177 Phase 1 Monotherapy Safety & Biomarker Data
ONCR-177 Phase 1 Monotherapy Safety & Biomarker Data Treatment-Related Adverse Events at RP2D 4x108 (RP2D) N=9 4x108 (RP2D) N=9 Preferred Term Grades 1-2 N (%) Preferred Term Grades 1-2 N (%) Any Event 7 (77.8) Cellulitis of face 1 (11.1) Fatigue 4 (44.4) Pain in knee 1 (11.1) Injection site pain 1
Slide 9: Potential ONCR-177 Combination Registration Plans
Potential ONCR-177 Combination Registration Plans Setting US Market Size Regimen Current Benchmark 2/3L Melanoma Post anti-PD-1 & anti-CTLA-4 ~6,000 pts/year ONCR-177 + Keytruda vs. investigator’s choice Dacarbazine: 10.3% ORR 2.5 months mPFS 9.1 months mOS1 3L TNBC 2 prior lines of therapy in metas
Slide 10: 4x10^8 selected as RP2D based on safety and preliminary activity
4x108 selected as RP2D based on safety profile observed to date and preliminary clinical activity Favorable safety profile (no Grade 3+ TRAEs) allows for optionality with combination partners and the opportunity to move into earlier settings, such as neoadjuvant Preliminary biomarker data support sy
Slide 11: Repeat IV administration via self-amplifying vRNA in an LNP
Repeat IV administration via selectively self-amplifying viral RNA (vRNA) encapsulated in an LNP vRNA selectively self-amplifies in immunosuppressed environments (tumors) & then produces oncolytic virions which further self-amplify Neutralizing antibodies (nAbs) inhibit efficacy of natural virus but
Slide 12: IV-administered Selectively Self-Amplifying vRNA
IV-administered Selectively Self-Amplifying vRNA 1. Ehrlich & Bacharach, Cancers, (2021); 2. Pol, et al., Cytokine Growth Factor Rev (2020) Animated walkthrough of the mechanism here
Slide 13: ONCR-021 is a Selectively Self-Replicating CVA21 Virus
ONCR-021 is a Selectively Self-Replicating CVA21 Virus IND Filing Expected Mid-’23 ICAM1 expression is prevalent in ONCR-021 selected clinical indications NSCLC HCC RCC 200 um 200 um 200 um Contains the genome of an optimized Coxsackievirus A21 (CVA21) strain, encapsulated in an LNP Oncolytic activi
Slide 14: ONCR-021: well tolerated with minimal replication in normal tissues
Well tolerated in huICAM-1 transgenic mouse model ONCR-021: well tolerated w/ min. replication in normal tissues hICAM-1 transgenic mouse model. (-) negative strand RNA indicates active replication. Minimal replication in normal tissues No effects on body weight No adverse elevation of liver enzymes
Slide 15: Preclinical Program ONCR-GBM
Preclinical Program ONCR-GBM IND Filing Expected 2H’23 1. Todo, et al, SNO, 2019; 2. Wick, et al, NEJM 2017 3. Wen, et al, N Oncol 2020; 4. Strathdee, et al. IOVC. 2021. GL261-luc-N Model (HSV backbone) (HSV backbone expressing mIL-12) (HSV backbone expressing aPD-1) (HSV backbone expressing mIL-12
Slide 16: Preclinical Program ONCR-788 for neuroendocrine tumors
Preclinical Program ONCR-788 for neuroendocrine tumors Encodes selectively self amplifying vRNA encoding for the synthetic Seneca Valley Virus (SVV) Targets SCLC & neuroendocrine prostate Induces tumor regression & improves survival in challenging SCLC xenograft models* Anti-PD-1 combination improve
Slide 17: ONCR-177 has Distinct Advantages Over Other RNA or Viral Therapies
Technology Virus Virus CpG mRNA mRNA Personalized Cancer Vaccine Programs ONCR-177 RP1, RP2, RP3 CMP-001 mRNA-2752 CV8102 mRNA-4157 BNT122 Immunogenic oncolysis? - - - - - Payloads 5 1-3 1 3 1 - - Antigens Viral + in situ vaccination Viral + in situ vaccination In situ vaccination In situ vaccin
Slide 18: IV RNA & Viral Immunotherapy Landscape
IV RNA & Viral Immunotherapy Landscape Viral RNA (vRNA) genome Viral capsid proteins Antibody response Lipid nanoparticle (LNP) Selectively self amplifies and spreads in tumor cells Potential to evade neutralizing antibodies RNA Virus Synthetic RNA virus PEG Lipid Pandha, H., et al., Abstract CT115,
Slide 19: Multiple Competing Companies Often Win When New Technologies Develop
Multiple Competing Companies Often Win When Transformative New Technologies are Developed Rare for there to be a sole winner when meaningful new technologies are developed, even for the 1st movers Oncorus has distinct technical advantages over others in the viral immunotherapy space Market Cap / Acq
Slide 20: Delivering Multiple Programs via In-House Manufacturing
Robust supply chain is critical to the successful development of any drug candidate & is a strategic asset Better able to respond to unexpected volatility & pressure on supply chains – robustness Able to manage multiple programs simultaneously – critical to authentic platform companies Limit burdens
Slide 21: Proven Leadership Team
Proven Leadership Team Ted Ashburn, Christophe Quéva, John McCabe, Stephanie John Goldberg, Steve Harbin Brett Belongia, Lorena Lerner, MD, PhD PhD MBA Duncanson, PhD MD PhD PhD President & CEO CSO CFO VP Strategy & BD SVP Clinical Dev. COO & Chief of Staff VP CMC Operations VP Molecular Biology Boa
Slide 22: Upcoming Catalysts
Mid-2022 Additional data from surface lesion monotherapy expansion cohorts Late-2022 Data from surface lesion combination cohorts Mid-2023 IND filing for ONCR-021 In-house GMP facility operational Begin registration-directed trials for ONCR-177 2H 2023 IND filing for ONCR-GBM Cash through late 2023*
Slide 23: Mission to eradicate cancer with viral immunotherapies
Mission is to eradicate cancer by exploiting and enhancing viruses’ natural ability to infect immunosuppressed tumor environments and attract the immune system Preliminary Phase 1 data of iTu ONCR-177 monotherapy demonstrated favorable tolerability, biomarkers to support MOA & rapid clinical benefit
Slide 24: Viral Immunotherapies for Cancer
Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR